Roche Reports 6% Constant-Currency Sales Growth in First Half of 2026 as Pipeline Delivers Five FDA Priority Reviews
Image
SHERIDAN, WYOMING -- July 30, 2026 -- Roche Holding AG closed the first half of 2026 with group sales up 6% at constant exchange rates, even as a strengthening Swiss franc pushed reported CHF results down 2%. The Basel-based healthcare company credited high demand for its medicines and diagnostics portfolios, alongside a wave of regulatory and clinical progress spanning oncology, neurology and ophthalmology. Five separate products received US Priority Review designations during the period, and Roche launched its Axelios 1 next-generation sequencing platform. For buyers and healthcare operators tracking supplier stability, the results signal continued capacity for both commercial delivery and pipeline investment despite currency headwinds.